Parsaclisib in Newly Diagnosed Stage I-IIIC Triple Negative or HER2+ Breast Cancer
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Breast Neoplasms|Triple Negative Breast Cancer|HER2-positive Breast Cancer
Interventions: DRUG: Parsaclisib
Sponsor: UNC Lineberger Comprehensive Cancer Center
Collaborators: Incyte Corporation